

OmvoH IV and SC to have an additional step therapy requirement for most commercial members starting Jan. 17

For dates of service on or after Jan. 17, 2025, members must try and fail two additional preferred products before we approve prior authorization requests for OmvoH™ IV and SC (mirikizumab-mrkz), HCPCS code J2267.

The additional preferred products for OmvoH IV and SC are:

- Skyrizi® IV and SC (risankizumab-rzaa), HCPCS code J2327
- Tremfya® IV and SC (guselkumab), HCPCS code J1628

For Skyrizi and Tremfya:

- The member must try and fail both the IV loading and SC maintenance doses.
- Providers must comply with any prior authorization and site-of-care requirements that apply under the applicable benefit.

For OmvoH IV and SC:

- See the [April 19, 2024, provider alert](#) for information about existing step therapy requirements.
- Step therapy requirements apply to most Blue Cross Shield of Michigan and Blue Care Network group and individual commercial members.
- Providers should continue to submit prior authorization requests through the NovoLogix® online tool.

By Jan. 17, we'll update the [Blue Cross and BCN utilization management medical drug list](#) to reflect the preferred drugs.

Some Blue Cross commercial groups aren't subject to these requirements

For Blue Cross commercial, these requirements apply only to groups that participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the [Specialty Pharmacy Prior Authorization Master Opt-in/out Group list](#).

Note: Blue Cross and Blue Shield Federal Employee Program® members and UAW Retiree Medical Benefits Trust (non-Medicare) members don't participate in the standard prior authorization program.



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Provider alert

Blue Cross commercial and BCN commercial

Categories: Authorizations/referrals, Pharmacy

Date posted: Dec. 4, 2024

Additional information

For more information about medical benefit drugs, see the following pages on ereferrals.bcbsm.com:

- [Blue Cross Medical Benefit Drugs](#)
- [BCN Medical Benefit Drugs](#)

Prior authorization isn't a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.

NovoLogix® is an independent company that provides an online prescription drug prior authorization tool for Blue Cross Blue Shield of Michigan and Blue Care Network.